Department of Radiotherapy(Su Tingfeng Current Employer:Department of Oncology,Huadu district,Guangzhou City People’s Hospital,510800,Guangzhou 510800,China),Teaching Hospital of Fujian Medical University,Fujian Provincial Cancer Hospital,Fuzhou 350014,China
Objective To analyze the prognosis of advanced esophageal carcinoma treated with paclitaxel and different platinum-based chemotherapy regimens plus intensity-modulated radiotherapy (IMRT), and to explore an optimal chemotherapy regimen. Methods A total of 242 patients with advanced esophageal carcinoma who were admitted to our hospital and treated with paclitaxel and cisplatin (68 patients), nedaplatin (85 patients), lobaplatin (58 patients), or oxaliplatin (31 patients) plus IMRT from 2008 to 2014 were enrolled as subjects. The prognosis of the four groups was analyzed after 2, 3, and ≥4 cycles of chemotherapy. The survival rates were calculated by the Kaplan-Meier method and analyzed by the log-rank test. The Cox model was used for the multivariate prognostic analysis. Results The sample number of 3 years was 168 cases. In all the 242 patients, the medium survival time was 31.1 months and the 3-year overall survival (OS) rate was 47.4%. There was no significant difference in the 3-year OS rate between the cispaltin, nedaplatin, lobaplatin, and oxaliplatin groups (46.2% vs. 56.4% vs. 45.7% vs. 29.0%, P=0.090). The stratified analysis showed that the cisplatin, nedaplatin, and lobaplatin groups had a significantly higher OS rate than the oxaliplatin group (50.1% vs. 29.0%, P=0.021). There was no significant difference in the 3-year OS rate between patients receiving 2, 3, and ≥4 cycles of chemotherapy (40.1% vs. 49.5% vs. 50.8%, P=0.264). The multivariate analysis showed that esophageal tumor volume and the maximal size of metastatic lymph node were independent prognostic factors. Conclusions Combined with IMRT, paclitaxel plus cisplatin, nedaplatin, or lobaplatin-based chemotherapy achieves improved survival rates than paclitaxel plus oxaliplatin-based chemotherapy. Esophageal tumor volume and the maximal size of metastatic lymph node are independent prognostic factors.
Chen Junqiang,Su Tingfeng,Lin Yu et al. The prognostic impacts of IMRT combined with chemotherapy with different platinums and paclitaxel in advanced esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(1): 35-39.
Chen Junqiang,Su Tingfeng,Lin Yu et al. The prognostic impacts of IMRT combined with chemotherapy with different platinums and paclitaxel in advanced esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(1): 35-39.
[1] Freilich J,Hoffe SE,Almhanna K,et al. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer[J].Dis Esophagus,2015,28(4):352-357.DOI:10.1111/dote.12203.
[2] 刘晓,王贵齐,贺舜,等.探讨非手术食管癌临床分期有效性与预测预后价值[J].中华放射肿瘤学杂志,2014,23(1):17-22.DOI:10.3760/cma.j.issn.1004-4221.2014.01.005.
Liu X,Wang GQ,He S,et al. Efficacy and predictive value of clinical stage in non-surgical patients with esophageal cancer[J].Chin J Radiat Oncol,2014,23(1):17-22.DOI:10.3760/cma.j.issn.1004-4221.2014.01.005.
[3] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01).Radiation Therapy Oncology Group[J].JAMA,1999,281(17):1623-1627.DOI:10.1001/jama.281.17.1623.
[4] Kato K,Muro K,Minashi K,et al. Phase Ⅱ study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage Ⅱ-Ⅲ esophageal squamous cell carcinoma:JCOG trial (JCOG 9906)[J].Int J Radiat Oncol Biol Phys,2011,81(3):684-690.DOI:10.1016/j.ijrobp.2010.06.033.
[5] Tang HR,Ma HF,An SM,et al. A phase Ⅱ study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma[J].Am J Clin Oncol,2016,39(4):350-354.DOI:10.1097/coc.0000000000000069.
[6] Song T,Zhang XB,Fang M,et al. Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer[J].Onco Targets Ther,2015,8:3087-3094.DOI:10.2147/OTT.S92537.
[7] McKeage MJ.Lobaplatin:a new antitumour platinum drug[J].Expert Opin Investig Drugs,2001,10(1):119-128.DOI:10.1517/13543784.10.1.119.
[8] Shen ZT,Wu XH,Li B,et al. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma[J].World J Gastroenterol,2013,19(48):9447-9452.DOI:10.3748/wjg.v19.i48.9447.
[9] 林宇,陈俊强,李建成,等.洛铂联合紫杉醇同步放化疗对中晚期食管癌的近期疗效[J].肿瘤研究与临床,2012,24(2):105-107.DOI:10.3760/cma.j.issn.1006-9801.2012.02.010.
Lin Y,Chen JQ,Li JC,et al. Recent results of concurrent chemoradiotherapy with lobaplatin and paclitaxel in advanced esophageal carcinoma[J].Cancer Res Clinic,2012,24(2):105-107.DOI:10.3760/cma.j.issn.1006-9801.2012.02.010.
[10] O'Connor BM,Chadha MK,Pande A,et al. Concurrent oxaliplatin,5-fluorouracil,and radiotherapy in the treatment of locally advanced esophageal carcinoma[J].Cancer J,2007,13(2):119-124.DOI:10.1097/PPO.0b013e318046ee1a.
[11] Jatoi A,Murphy BR,Foster NR,et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus,gastroesophageal junction and gastric cardia:a phase Ⅱ study from the North Central Cancer Treatment Group[J].Ann Oncol,2006,17(1):29-34.DOI:10.1093/annonc/mdj063.
[12] Kwong DLW,Sham JST,Au GKH,et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma:a factorial study[J].J Clin Oncol,2004,22(13):2643-2653.DOI:10.1200/JCO.2004.05.173.
[13] Chen L,Hu CS,Chen XZ,et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma:a phase 3 multicentre randomised controlled trial[J].Lancet Oncol,2012,13(2):163-171.DOI:10.1016/S1470-2045(11)70320-5.
[14] Chen JQ,Pan JJ,Liu J,et al. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2013,86(4):671-677.DOI:10.1016/j.ijrobp.2013.03.026.
[15] 万欣,乔学英,王雅棣,等.131例食管鳞癌三维适形放疗预后因素分析[J].中华放射肿瘤学杂志,2011,20(3):202-204.DOI:10.3760/cma.j.issn.1004-4221.2011.03.009.
Wan X,Qiao XY,Wang YD,et al. Analysis of treatment outcome and prognostic factor with three-dimensional conformal radiotherapy for thoracic esophageal squamous cell carcinoma[J].Chin J Radiat Oncol,2011,20(3):202-204.DOI:10.3760/cma.j.issn.1004-4221.2011.03.009.
[16] Edge S,Byrd DR,Compton CC,et al. AJCC cancer staging handbook:from the AJCC cancer staging manual[M].7th ed. New York:Springer,2010.
2017, Vol. 26 
